Published: Fri, May 18, 2018
Medical | By Johnnie Horton

The FDA approved a prophylactic for migraines

The FDA approved a prophylactic for migraines

USA regulators have approved the first drug created to prevent chronic migraines.

Aimovig is the first in a new class of treatments created to prevent migraine by interfering with calcitonin gene-related peptide (CGRP), which is involved in the processes that kick off a migraine, such as dilation of blood vessels in the brain.

The drug named, Aimovig is given on a monthly basis by self-injections and will be priced at Dollars 6,900 annually or USD 575 monthly. "We look forward to working closely with Amgen in the bring this treatment to physicians and their patients, who could now gain days of their lives back each month". "We need new treatments for this painful and often debilitating condition".

Approximately one-third of affected individuals can predict the onset of a migraine because it is preceded by transient sensory or visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision.

Around one in seven people worldwide experience migraines, among them 37 million Americans, the New York Times reported.

Guardiola Extends Manchester City Stay To 2021
Manchester City manager Pep Guardiola has signed a new long-term contract with the club, it was confirmed on Thursday. Completing five years at the Abu Dhabi-owned club would represent Guardiola's longest tenure in a coaching job.

The attacks are triggered by a number of factors, "including stress, hormonal changes, bright or flashing lights, lack of food or sleep, and diet".

The US regulator said the effectiveness of the new drug was tested in three clinical trials.

Erenumab consistently demonstrated an ability to reduce monthly migraine days in patients with episodic and chronic migraine in 3 major clinical trials, ARISE, STRIVE, and LIBERTY. Over the course of three months, Aimovig-treated patients experienced, on average, one fewer migraine day per month than those on placebo.

The drug has been evaluated in more than 3000 patients, and its efficacy, tolerability, and safety continue to be examined in an ongoing 5-year open-label extension study. However, there were side-effects too - namely injection-site reactions and constipation.

Like this: